Anti-HBV effects of CpG oligodeoxynucleotide-activated peripheral blood mononuclear cells from patients with chronic hepatitis B

APMIS

Volumn 113, Issue 10, 2005, Pages 647-654

  Li, Ning ^a   Fan, Xue Gong ^a   Chen, Zhao Hui ^b   Huang, Yan ^a   Quan, Jun ^a   Liu, Zheng Bo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; CpG oligodeoxynucleotides; Hepatitis B virus; Interferon ; PBMCs

Indexed keywords

BACTERIAL DNA; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; OLIGODEOXYNUCLEOTIDE; VIRUS DNA;

ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CELL CULTURE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNITY; IMMUNOREGULATION; IMMUNOSTIMULATION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL; VERTEBRATE; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 28844492614     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2005.apm_218.x     Document Type: Article

References (45)

1. Wagner H. Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol 2002;5:62-9.
2. Ashkar AA, Rosenthal KL. Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med 2002;2:545-56.
3. Heeg K, Zimmermann S. CpG DNA as a Th1 trigger. Int Arch Allergy Immunol 2000;121:87-97.
4. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60.
5. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:1-10.
6. Walker PS, Scharton-Kersten T, Krieg AM, Love-Homan L, Rowton ED, Udey MC, et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci USA 1999;96:6970-5.
7. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998;160:3627-30.
8. Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 1999;67:3719-26.
9. Krieg AM, Yi AK, Schorr J, Davis HL. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 1998;6:23-7.
10. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999;162: 2291-8.
11. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Huffman SL. Interleukin-12-and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun 2001;69:1643-9.
12. Juffermans NP, Leemans JC, Florquin S, Verbon A, Kolk AH, Speelman P, et al. CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun 2002;70:147-52.
13. Schlaepfer E, Audige A, von Beust B, Manolova V, Weber M, Joller H, Bachmann MF, Kundig TM, Speck RF. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol 2004;78:12344-54.
14. Ashkar AA, Bauer S, Mitchell WJ, Vieira J, Rosenthal KL. Local delivery of CpG oligodeoxynucleotides induces rapid changes in the genital mucosa and inhibits replication, but not entry, of herpes simplex virus type 2. J Virol 2003;77:8948-56.
15. Harandi AM, Eriksson K, Holmgren J. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. J Virol 2003; 77:953-62.
16. Dong L, Mori I, Hossain MJ, Liu B, Kimura Y. An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response. J Gen Virol 2003;84:1623-8.
17. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5.
18. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001;167:3555-8.
19. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
20. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 2001;166:2372-7.
21. Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 2003;109:64-71.
22. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38:S158-68.
23. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
24. Locarnini S. A virological perspective on the need for vaccination. J Viral Hepat 2000;7:S5-6.
25. Fan XG, Huang Y, Tang FQ, Yi H. Telomerase activity of peripheral blood lymphocytes in patients with chronic hepatitis B. Immunol Lett 2000;73:7-11.
26. Beckebaum S, Cicinnati VR, Dworacki G, Muller-Berghaus J, Stolz D, Harnaha J, et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002;104:138-50.
27. Arima S, Akbar SM, Michitaka K, Horiike N, Nuriya H, Kohara M, et al. Impaired function of antigen-presenting dendritic cells in patients with chronic hepatitis B: localization of HBV DNA and HBV RNA in blood DC by in situ hybridization. Int J Mol Med 2003;11:169-74.
28. van der Molen RG, Sprengers D, Binda RS, de Jong EC, Niesters HG, Kusters JG, et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004;40:738-46.
29. Duan XZ, Wang M, Li HW, Zhuang H, Xu D, Wang FS. Decreased frequency and function of circulating plasmocytoid dendritic cells (pDC) in hepatitis B virus infected humans. J Clin Immunol 2004;24:637-46.
30. Fan X, Zhang Z. Increased tumour necrosis factor alpha production by neutrophils in patients with hepatitis B. J Clin Pathol 1994;47:616-8.
31. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001;31:2154-63.
32. Rothenfusser S, Hornung V, Krug A, Towarowski A, Krieg AM, Endres S, et al. Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta. Eur J Immunol 2001;31:3525-34.
33. Fan XG, Kelleher D, Fan XJ, Xia HX, Keeling PW. Helicobacter pylori increases proliferation of gastric epithelial cells. Gut 1996;38:19-22.
34. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
35. Liu YJ, Kanzler H, Soumelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001;2:585-9.
36. O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994;82:487-93.
37. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-7.
38. Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP, Wagner H, et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol 2001;166:5000-7.
39. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000;1:305-10.
40. Gursel M, Verthelyi D, Klinman DM. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol 2002;32:2617-22.
41. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003;101:4505-11.
42. Auffermann-Gretzinger S, Keeffe EB, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001;97:3171-6.
43. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-54.
44. Kemp TJ, Elzey BD, Griffith TS. Plasmacytoid dendritic cell-derived IFN-alpha induces TNF-related apoptosis-inducing ligand/Apo-2L-mediated antitumor activity by human monocytes following CpG oligodeoxynucleotide stimulation. J Immunol 2003;171:212-8.
45. Conjeevaram HS, Lok AS. Management of chronic hepatitis B. J Hepatol 2003;38:S90-103.